Stem cell therapy for knee osteoarthritis in China

Umbilical-cord mesenchymal stem cells delivered into the joint under imaging guidance, in a licensed Boao Lecheng hospital — the zone’s most requested single program. What the trials found, what the guidelines still say, who it suits, and when a knee replacement is the better answer.

What stem cell therapy for knee osteoarthritis actually is

Mesenchymal stem cells (MSCs) are stromal cells found in connective tissue — in bone marrow, in fat, and in the jelly that cushions the vessels of the umbilical cord. They are not embryonic cells, and the name oversells them: their reliable, laboratory-demonstrable behaviour is not to turn into cartilage on demand but to signal. They secrete growth factors and cytokines, they migrate toward injured tissue, and they restrain the immune activity that keeps chronic injury simmering. Umbilical-cord MSCs (UC-MSCs) are isolated from donated cord tissue after a screened, consented birth, expanded in a licensed GMP facility, characterised against a specification, and released as a standardised product. Because MSCs carry little of the surface signature that provokes rejection, a cord-derived cell can be given to an unrelated adult without tissue matching.

Osteoarthritis of the knee is not simply cartilage wearing out. Cartilage loss is the visible end of it, but the joint behaves as an organ in slow failure: the synovial lining is chronically, mildly inflamed; the subchondral bone remodels and develops the marrow lesions that correlate with pain better than the cartilage does; osteophytes form at the margins; the capsule stiffens and the quadriceps wastes. That is why the standard X-ray grade and the patient’s actual suffering line up so poorly — people with alarming films who walk comfortably, and people with modest films in real pain.

The case for putting cells into that joint follows from the signalling story, not from the regeneration story. The intent is to damp the synovial inflammation, shift the balance of enzymes that degrade the cartilage matrix back toward preservation, and alter the chemical environment the remaining cartilage lives in. Whether new cartilage of load-bearing quality grows back is a separate and much weaker claim, and this page separates the two deliberately.

Why an injection into the joint, and not an infusion

The cirrhosis program gives the same cell type as a slow intravenous infusion, because the target organ is reached through the bloodstream. A knee is not. The joint cavity is a closed, poorly vascularised compartment, and cells introduced into a vein arrive there in trivial numbers — most are trapped in the lungs within minutes of an intravenous dose. So the knee program is intra-articular: the cells are placed directly into the joint space, under imaging guidance, which is also how the homepage describes the program in a single line — umbilical-cord mesenchymal cells delivered into the joint under imaging guidance, targeting cartilage environment and inflammation.

Imaging guidance matters more than it sounds. Blind knee injections miss the joint space in a meaningful minority of attempts, particularly in a stiff or swollen knee, and a dose delivered into fat or capsule is a dose not delivered at all. Ultrasound guidance removes most of that error, and it lets the clinician aspirate an effusion first, which both relieves pressure and stops the dose being diluted in a joint full of fluid.

Is stem cell therapy for knees legal in China?

Inside the Boao Lecheng pilot zone, yes, and the qualifier matters. Knee osteoarthritis sits among the named conditions across the zone’s five approval batches of cell and gene technologies — alongside liver cirrhosis, type-2 diabetes, chronic lung disease and ischaemic heart failure — and it is delivered as clinical-stage disease treatment in a tertiary hospital, with filed inclusion and exclusion criteria and mandatory reporting of every course into China’s national real-world data program.

State Council Order No. 818, in force since 1 May 2026, is what draws the line nationally: cell therapy on the mainland is confined to disease indications, delivered by qualified institutions under filed protocols. An arthritic knee with a radiographic diagnosis is a disease indication. “Joint rejuvenation” in a healthy forty-year-old is not, and a clinic offering the same injection on that basis is outside the licence rather than at its edge. Our own guide to Order 818 and the 2026 rules is the fuller explanation, and the six questions at the end of it are the ones to put to any provider in any country.

What the evidence shows — and what it does not

This is the section most pages in this category skip, so it is worth being plain. There is now a substantial randomised literature on intra-articular MSCs for knee osteoarthritis, using bone-marrow-derived, adipose-derived and umbilical-cord-derived cells. Several trials — including repeated-dose UC-MSC compared against hyaluronic acid — have reported improvements in validated pain and function scores, WOMAC and VAS among them, sustained across six to twenty-four months. Pooled analyses generally find a benefit on those symptom scores against control. Safety findings are reassuring and consistent: transient injection-site pain and swelling, occasional effusion, no pattern of serious cell-related harm.

Now the other half. Structural evidence — cartilage volume or thickness on MRI, scored by instruments such as MOAKS or WORMS — is inconsistent and much weaker than the symptom evidence. Trials are mostly small, the cell products differ so much between studies that pooling them is arguably a category error (source tissue, dose, passage number, single versus repeated, carrier), follow-up rarely extends beyond two years, and the comparator problem is severe: an intra-articular injection of almost anything produces a large and durable placebo response, which is precisely why the field insists on saline-controlled designs and why uncontrolled before-and-after series should be discounted almost entirely.

That is why the major guideline bodies have not adopted it. The 2019 American College of Rheumatology and Arthritis Foundation guideline recommends against stem cell injection for knee osteoarthritis outside a trial, explicitly on the grounds of heterogeneous, unstandardised products and insufficient evidence; OARSI’s guidance is similarly unsupportive. We think a prospective patient should hear that from us rather than discover it afterwards. The defensible reading is this: the symptom evidence is real but modest and not yet guideline-grade, the structural claim is not established, and anyone telling you this regrows your cartilage is ahead of the data. What Boao Lecheng offers is not a way around that uncertainty — it is a way to enter it inside a licensed hospital, with a characterised product and a reported outcome, rather than at a clinic that has published nothing.

Who it suits, and who it does not

Candidacy is decided by the treating hospital’s panel after it reads your imaging and records. We do not pre-approve anyone, and no criteria on this page should be read as the hospital’s filing. What the published literature consistently describes, though, is a recognisable patient:

If both knees are involved, say so in your first message; whether they are treated in one visit is a panel decision and it changes the length of your stay.

How a course runs

After the injection

Expect a flare. A warm, swollen, more painful knee for one to three days after an intra-articular injection is common, self-limiting and not a sign of failure; ice, elevation and simple analgesia manage it, and the care team should hear about anything beyond that — fever, spreading redness, or pain that escalates rather than settles after seventy-two hours, which is the presentation of the one serious procedural risk, a septic joint. Rest the leg for the remainder of the procedure day. Over the following week, load it gently and normally rather than immobilising it: cartilage and synovium are maintained by movement, and a knee protected too carefully stiffens.

Keep the joint out of hot springs, pools and steam rooms until the puncture has closed — a real constraint on an island whose retreat includes them, so your care manager schedules the hydrotherapy days around the procedure day rather than leaving you to discover the clash. And then resume the strength work, which is the part everyone wants to skip. Quadriceps and hip-abductor strengthening remains the single best-evidenced treatment in knee osteoarthritis, better evidenced than any injection of anything. The cells are an adjunct to that programme, not a substitute for it, and a guest who flies home and stops exercising has spent the trip badly.

What it cannot do — and when a knee replacement is the better answer

It does not regrow a joint. It does not correct a deformity, repair a mechanical block from a displaced meniscal tear, or undo grade IV disease. It is not a longevity or anti-ageing treatment, and the same cell type marketed as one elsewhere is being offered outside the licence that makes this program lawful.

Most importantly, it is not a substitute for total knee replacement in the knee that needs one. Replacement is a mature operation with decades of national registry data behind it, high satisfaction in advanced disease, and implant survival measured in decades. Cell therapy has short follow-up and no registry of that kind. If you have a bone-on-bone knee with deformity, rest pain and night pain, the replacement is the better treatment and nothing here should delay it — the same principle that makes an imminent liver transplant an absolute exclusion on the cirrhosis program. The honest place for cell therapy is earlier: in the moderate joint, in the patient who wants to postpone an operation they will eventually have, as an attempt to buy comfortable years. Framed that way it is a reasonable thing to consider. Framed as an alternative to surgery you already need, it is not.

Cost, and why there is no price on this page

We publish no stem cell therapy prices. A figure attached to a treatment you may not qualify for is marketing rather than information, and the treating hospital quotes the course only after candidacy is confirmed. What a quote is built from — the manufacturing run, the number of doses, day-case admissions, monitoring and imaging — and what the four-day assessment retreat itself covers are set out in full in what a longevity program in China costs.

Why Boao Lecheng for a knee

Three things hold here that hold nowhere else on the mainland. The indication is licensed, and delivered in a tertiary hospital rather than a storefront clinic. The cell product is released on-site against a filed specification, with the failed batch destroyed rather than used. And outcome reporting is mandatory — every course enters a national real-world data program, which is the closest thing to a trial framework a patient can enter without being in a trial, and it is the reason an honest answer about the evidence is possible at all. Why Boao Lecheng → Hainan’s 30-day visa-free entry covers the stay for citizens of the countries on the list, and planning a trip to Hainan covers the flights, seasons and what to bring.

If you have knee osteoarthritis with a recent weight-bearing X-ray or MRI, write to us with the grade if you know it, what you have already tried, and what you want the knee to let you do again. A care manager will tell you honestly, within one working day, whether the panel is likely to consider you — including when the answer is that you should be talking to a surgeon instead.

Frequently asked

What is stem cell therapy for knee osteoarthritis?

Umbilical-cord mesenchymal stem cells (UC-MSCs) are stromal cells isolated from donated, screened cord tissue, expanded in a licensed GMP facility and released as a standardised cell product. For knee osteoarthritis they are delivered into the joint space itself under imaging guidance, rather than infused into a vein. The rationale is that the cells act on the joint environment — damping the low-grade synovial inflammation that drives pain, and shifting the chemical signalling that governs cartilage breakdown — rather than growing new cartilage to order.

Is stem cell therapy for knees legal in China?

Inside the Boao Lecheng pilot zone it is delivered as licensed clinical-stage disease treatment in a tertiary hospital, and knee osteoarthritis is one of the named indications across the zone's approval batches of cell and gene technologies. State Council Order No. 818, in force 1 May 2026, confines cell therapy on the mainland to disease indications with filed inclusion and exclusion criteria. A clinic elsewhere in China offering the same injection for general anti-ageing is not operating under that licence.

Does stem cell injection work for knee osteoarthritis?

Randomised trials of intra-articular mesenchymal stem cells, including repeated-dose UC-MSC against hyaluronic acid, have reported improvements in pain and function scores such as WOMAC and VAS over six to twenty-four months. The evidence for structural change — measurable cartilage regrowth on MRI — is far weaker and inconsistent. Major guidelines, including the 2019 American College of Rheumatology guideline, still recommend against stem cell injection for knee osteoarthritis outside a trial, citing small studies, unstandardised products and a large placebo effect from any intra-articular injection.

Who is a candidate for UC-MSC knee injection?

In the published literature the patients who do best have moderate radiographic disease — roughly Kellgren-Lawrence grade II to III — with pain and functional limitation, a joint that still has cartilage and reasonable alignment, and conservative measures already tried. Candidacy at Boao Lecheng is set by the treating hospital's panel after it reviews your imaging and records, not by us and not by a questionnaire.

Can stem cells replace a knee replacement?

No. Total knee replacement is a mature operation with decades of registry data and high satisfaction rates in advanced disease. Cell therapy is clinical-stage treatment with short follow-up and no registry of that kind. In a bone-on-bone knee with deformity and night pain, the replacement is the better answer and no injection should be used to postpone it. The honest position for cell therapy is earlier, in the moderate joint, as an attempt to buy comfortable years.

What happens after a stem cell injection into the knee?

A transient flare — a warm, swollen, more painful knee for one to three days — is common and self-limiting, and is not a sign that the injection failed. The knee is rested for the remainder of the day, loaded gently rather than immobilised over the following week, and kept out of hot springs, steam rooms and pools until the puncture has closed. Strength work resumes progressively, because the quadriceps is the single best-evidenced treatment for knee osteoarthritis and the injection does not replace it.

Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.